Details

Autor(en) / Beteiligte

• Rosenke, Kyle
• Hansen, Frederick
• Schwarz, Benjamin
• Feldmann, Friederike
• Haddock, Elaine
• Rosenke, Rebecca
• Barbian, Kent
• Meade-White, Kimberly
• Okumura, Atsushi
• Leventhal, Shanna
• Hawman, David W.
• Ricotta, Emily
• Bosio, Catharine M.
• Martens, Craig
• Saturday, Greg
• Feldmann, Heinz
• Jarvis, Michael A.

Titel

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Ist Teil von

• Nature communications, 2021-04, Vol.12 (1), p.2295-2295, Article 2295

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients. While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model.